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ABSTRACT
Objectives: We sought to identify chronic pain patients’ preferences for
levels of improvement in pain-related morbidity (PRM) by measuring their
willingness to pay (WTP) for reducing their pain intensity and pain-related
disability.
Methods: The study was a cross-sectional nonrandomized design. Partici-
pants were recruited from a tertiary multidisciplinary pain center in
Canada. A computer-administered discrete-choice experiment was used to
explore participants’ WTP for various levels of improvement to PRM.
Participants chose between two varying combination of treatments that
differed in terms of their level of improvement in pain intensity, level of
improvement in pain-related disability, and out-of-pocket monthly
cost.
Results: The WTP to completely minimize PRM was $1428 per month.
Reduction in pain intensity was valued more highly than functional
improvement. For every dollar, an individual was WTP to improve his/her
disability to the lowest severity (mild), he/she was WTP approximately $2
to reduce pain intensity to moderate and $3 to reduce pain intensity to
mild. The potential return on investment in terms of health improvement
gained was $3318 per patient visit per year.
Conclusion: The morbidity associated with chronic pain is worth
approximately $1428 for every month in the chronic pain health state.
From the patient’s perspective, treatment and management strategies that
focus on reducing pain intensity would have the greatest impact on
improving health-related quality of life. Valuing health improvement in
monetary terms allows for direct monetary comparisons between the costs
of chronic pain interventions and their associated health returns.
Keywords: burden of illness, health-state utility, pain, patient preferences,
willingness to pay.
Introduction
Chronic pain often occurs during the most productive years of
life [1]. The estimated cost of lost productivity in the United
States attributed to chronic pain is more than US$50 billion per
year [2] with other estimates between US$85 and US$95 billion
[3]. The full economic burden attributable to chronic pain is
underestimated because little information has been collected
about the intangible cost associated with the chronic pain health
state (i.e., the economic burden of pain and suffering).
Pain-related morbidity (PRM) is composed of both pain
intensity and pain-related disability [4]. Determining patient
preferences in terms of willingness to pay (WTP) for levels of
improvement to pain intensity and/or disability would provide
insights that would lead to more effective pain management
strategies because it would elucidate the relative value of improv-
ing pain intensity and/or disability for persons with chronic pain.
Obtaining the WTP for improvements in PRM also quantiﬁes the
economic burden (i.e., intangible cost of pain and suffering) of
chronic pain itself. Accordingly, the objective of the study was to
identify chronic pain patients’ preferences for levels of improve-
ment in PRM by measuring their WTP for reducing pain intensity
and/or improving disability in the context of a specialized pain
center.
Methods
Population and Setting
A cross-sectional nonrandomized study design was conducted in
the University of Alberta Hospital Multidisciplinary Pain Centre
in 2007. Schedule of operation was from Monday to Thursday
from 8:00 am to 4:30 pm. Patients attending the center were
referred by their primary care physician. Patients attending the
center undergo a triage and evaluation process by a pain special-
ist to identify inappropriate referrals (i.e., severity and complex-
ity of their chronic pain condition can be managed through a
primary care physician). Patients whose referral is deemed in-
appropriate are either placed on a waiting list or expedited
if clinically appropriate. Nonpharmaceutical interventions are
covered by the Alberta Health Care System. For pharmaceutical
interventions, the majority of patients are required to provide a
copayment through their insurance plans. Patients with lesser
incomes who do not have insurance coverage for prescription
medications are referred to social services to apply for ﬁnancial
assistance.
The study population was a random sample of individuals
with chronic pain, who were 20 years and older who were not
ﬁrst-time attendees. Those who were involved in litigation or an
insurance claim were excluded because of potential strategic
behavior and bias. Ethical approval was obtained from the Uni-
versity of Alberta Health Research Ethics Board, and written
informed consent was obtained from each study participant.
Pain-Related Health Status (PRHS)
Self-reported PRHS was determined by using standard clinical
measures, including the Faces Pain Scale [5] and the Pain
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Disability Index [6–8]. In addition to having been validated for
use in chronic pain populations [5–8], both these instruments are
regularly used for assessing pain and disability in both research
and clinical protocols at the multidisciplinary pain center, and
respondents were therefore familiar with these instruments.
Moreover, both measures were modiﬁed to facilitate comprehen-
sion based on information generated from pilot testing (Fig. 1).
During pilot testing, it was determined that qualitative descrip-
tive ranking used in combination with graphical illustrations
improved respondent understanding of the various severities of
pain intensity and disability. The use of visual aids in stated
preference valuation techniques is also supported by relevant
research [9].
Based on these levels of pain intensity and disability, partici-
pants were classiﬁed into one of eight health states: total disability
and excruciating pain (TDEP), total disability and severe pain
(TDSP), total disability and moderate pain (TDMP), severe dis-
ability and excruciating pain (SDEP), severe disability and severe
pain (SDSP), moderate disability and excruciating pain (MDEP),
and moderate disability and severe pain (MDSP). No individuals
presented with moderate pain intensity–moderate disability, mod-
erate pain intensity–severe disability, nor were there any individu-
als with mild pain intensity or mild disability during pilot testing.
WTP Questionnaire
WTP was elicited using a set of discrete-choice experiments
(DCE) [10–13]. We sought to obtain an unbiased measure that
represented only the burden of chronic pain by measuring WTP
independent of treatment modality or other treatment factors
(e.g., mode of administration, side effects, duration of improve-
ment, etc.). Therefore, the DCE measured the WTP for treat-
ments that improved pain intensity and/or disability, keeping all
other treatment aspects identical.
Participants were presented with a series of choice scenarios
where they could buy one of two hypothetical treatments that
differed in three attributes: level of improvement in pain inten-
sity, level of improvement in pain-related disability, and monthly
out-of-pocket price. In each choice question, levels of improve-
ment to pain intensity and disability were represented by graphi-
cal illustrations that replicated the categories used for measuring
PRHS described above (Fig. 2). After initial pilot testing, the
out-of-pocket prices for each treatment ranged between $100
and $1000 per month. Better treatments were associated with
higher price to ensure that participants would make trade-offs
between improvements and price. This was also conducted to
promote realism in the WTP questionnaire and the validity of
choice responses because in real clinical settings, effective treat-
ments are usually associated with higher costs.
Levels of improvements in the choice scenarios were depen-
dent on the presenting individual’s PRHS because WTP was
based on treatments that improved upon one’s PRHS. Therefore,
a different WTP questionnaire was given to individuals with each
presenting PRHS. WTP for improvements to no pain and no
disability was not assessed because pilot testing revealed that
including levels of “no pain” or “no disability” in the question-
naires compromised realism (e.g., a proportion of participants
stated that such treatment outcomes were unrealistic). Therefore,
there were seven separate questionnaires designed for individuals
presenting with TDEP, TDSP, TDMP, SDEP, MDEP, SDSP, and
MDSP. Questionnaires were designed to maximize orthogonality
(i.e., minimize collinearity between attribute levels promoting
statistical efﬁciency) and level balance (i.e., ensure attributes
levels have an equal frequency of appearing throughout the ques-
tionnaire to minimize choice bias). An assessment of orthogonal-
ity found that correlations (Kendal-Tau) between treatment
attributes were less than 0.40 for all the questionnaires, with the
great majority of correlations being lower than 0.15. An assess-
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Figure 1 Instruments used for assessing pain
intensity and pain-related disability.
Instruments were adapted from the Facial Pain
Scale [5] and the Pain Disability Index [6–8] based
on information generated from pilot testing.
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ment of level balance found that attribute levels had a relatively
equal frequency of appearing throughout each questionnaire.
Other Data
A demographic questionnaire was used to collect information on
demographics, clinical history, and debrieﬁng questions concern-
ing the WTP questionnaire. Demographic information included
marital status, smoking status, level of education, income, and
other chronic conditions (e.g., diabetes). Debrieﬁng questions
included questions that targeted protest bias (i.e., Did respon-
dents object to the questionnaire?), consequentiality (i.e., Was the
questionnaire realistic and did individuals make trade-offs seri-
ously?), ease of questionnaire, certainty in buying treatments,
and the importance of treatment attributes. Information concern-
ing clinical history included number of years with pain. Primary
pain diagnosis, date of admittance, and date of birth was
obtained from medical charts.
Procedure
PRHS, WTP, and background questionnaires were administered
in person by a single investigator. A clinic schedule of patients
was obtained for each data collection day. Each patient in the list
was assigned a number from which four individuals were ran-
domly selected to participate in the study using a random number
generator in Microsoft Excel. Individuals who preferred not to
participate in the study were not replaced with another patient
from the clinic schedule.
PRHS was assessed using the questionnaire shown in
Figure 1. Participants were asked to indicate which of the illus-
trations best characterized their level of pain intensity, and
second, the degree to which their pain affected their ability to
conduct family activities, recreation, socialization, employment,
and self-care.
Based on an individual’s PRHS, a corresponding set of choice
questions was loaded on a laptop computer screen. The partici-
pant was told that he/she would be presented with a series of
treatments where he/she could buy either treatment A or B, or
neither treatment. He/she was told that treatments A and B
differed in the level of improvement of pain intensity, level of
improvement of pain-related disability, and out-of-pocket cost
per month after insurance. He/she was told that all other aspects
of the treatment were identical (i.e., side effects, duration, and
mode of administration). This was followed by a “cheap talk
script” [14] indicating that although the choices were hypotheti-
cal, participants were to treat each choice seriously and to
pretend that their choice was binding (i.e., that they would have
to actually pay the price associated with the treatment chosen).
Previous research has shown that cheap talk employed in choice
experiments improves consequentiality and validity of WTP esti-
mates [14]. Participants were given three practice questions
before starting the WTP questionnaire. While completing the
questionnaire, participants could refer to Figure 1 at any time.
After the WTP questionnaire, the background and debrieﬁng
questionnaire was given. The entire assessment including obtain-
ing consent and administering questionnaires took approxi-
mately 20 minutes to complete. Data were collected over a
6-month period beginning in September 2006.
Analysis
Analysis of DCE data was conducted using two nested logistic
regression models [13]. In the ﬁrst model, we estimated WTP for
improvements in PRHS excluding demographic or clinical vari-
ables (base model). This provided an overall mean estimate of
WTP for each attribute and level of improvement. Attribute
levels for pain intensity and pain-related disability were dummy
coded using no change as the reference category. Cost of treat-
ments was entered as a continuous variable. Alternative-speciﬁc
constants for treatments A, B, and “neither option” were also
included in the models. Adding constants for treatment A and B
controlled the potential that there could be a preferential differ-
ence between treatment A and treatment B, irrespective of the
treatment attributes (i.e., pain relief, disability improvement and
cost) [13].
The second model (base + demographics) was identical to the
ﬁrst model except that it included demographic and clinical
variables. WTP may vary with attributes of treatment as well as
characteristics of the patient [15], and this model provided
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Figure 2 Example of a discrete-choice question.
Individual is presenting with Severe Disability and
Severe pain intensity. Improvements are based
upon presenting pain-related health status and
replicate the graphical illustrates used to assess
pain-related health status shown in Figure 1.
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individual-speciﬁc WTP estimates by demographic and clinical
factors. Because discrete-choice data are structured as panel data,
incorporating demographic and clinical variables in the regres-
sion model required creating interaction terms between the
dummy variables of the DCE attributes (i.e., levels of improve-
ment in PRD and pain intensity) with demographic and clinical
variables. Categorical demographic and clinical variables were
effects coded [16,17]. Effects coding is similar to dummy coding
where L-1 variables are created. The difference between effects
and dummy coding is that the reference level is coded 1 instead
of 0. As a result, the effects of the reference level (within a
categorical variable) is uncorrelated with the constant term but is
instead internalized in the b estimates allowing one to estimate
the effects of the reference level from the coefﬁcients themselves
independent of the constant term.
Demographic variables included age (continuous), sex,
marital status (single/separated/divorce, married/common-law),
smoking status (current smoker, nonsmoker), level of education
(did not complete postsecondary, completed postsecondary), and
total annual household income. Income was coded into two
dummy variables comparing total household incomes less than
$30,000 with incomes $30,000 to $59,999 and incomes greater
than $59,999. Clinical variables included months as a patient
(continuous), number of years with pain (continuous), total
number of comorbidities (continuous), and presence of depres-
sion (no, yes).
We hypothesized that preference for pain relief is affected by
length of time as a patient, number of years living with chronic
pain, and total number of comorbidities. Psychological distress
and depression are known to be associated with chronic pain
[18–20]. Therefore, clinical variables included months as a
patient (continuous), number of years with chronic pain (con-
tinuous), total number of comorbidities (continuous), and pres-
ence of depression (yes, no).
Validity and Sensitivity Analysis
Three approaches were employed to increase the validity of our
WTP ﬁndings. First, embedding effects (i.e., bias resulting from
the sequence of questions or because treatment alternatives are
presented in isolation of other available alternatives) and use of
heuristics were tested by incorporating tests for consistency (i.e.,
Do participants answer the same question the same way?) and
transitivity (i.e., Are their preferences for levels of improvements
consistent throughout the questionnaire?) into the WTP ques-
tionnaire [10,13].
Second, content validity was formally tested by determining
whether WTP was positively associated with higher income and
self-reported preferences for DCE attributes. For example, WTP
for pain reduction should be higher than the WTP for disability
improvement for individuals who indicated that reducing pain is
more important than improving disability. This was conducted in
separate multinomial logistic regression models, which added
self-reported preferences to the base + demographic model.
Third, we compared the WTP between individuals who
indicated or did not indicate protest bias, lack of consequenti-
ality, and purchase uncertainty in the base model. Protest bias
was deﬁned as individuals indicating they did not agree with
paying for treatments. Lack of consequentiality was deﬁned as
indicating the following responses: improvements were good
and individuals knew they did not have to pay for treatments;
individuals did not believe level of improvement, or treatments
were unrealistic. Uncertainty was deﬁned as individuals indicat-
ing they were uncertain of whether they would purchase the
treatments chosen.
Statistical Analysis
A linear additive model assumes that each attribute has an
independent and linear effect on preferences [13]. The nested
logistic regression analyses for both the base and base +
demographic model were conducted separately for each version
of the WTP questionnaire (i.e., for each presenting pain-related
health state) but also for a data set that pooled the WTP data
across individual health states. STATA 9.1 (StataCorp LP,
College Station, TX) was used to analyze the DCE data. Model
ﬁt was assessed using pseudo R2. Model coefﬁcients were con-
sidered statistically signiﬁcant at P < 0.05. Power calculations
for determining the sample size for DCEs are based on the
number of choice questions contained in the WTP question-
naire [10–13]. A power calculation was conducted to determine
the appropriate sample size for each WTP questionnaire. WTP
questionnaires for individuals presenting with TDEP, TDSP,
TDMP, SDEP, MDEP, SDSP, and MDSP contained 34, 25, 16,
25, 16, 18, and 11 choice questions that required 11, 15, 24,
15, 21, 24, and 35 participants, respectively, at a = 0.05.
Calculating WTP
Each regression coefﬁcient in the models represents the mar-
ginal effects of each attribute (amount of satisfaction gained
from consuming one additional unit of that attribute). There-
fore, dividing the marginal rates of substitution between the
attributes and the price represents the trade-off between the
satisfaction gained from “buying” that attribute and the cost of
“buying” that attribute. Therefore, the WTP for any particular
treatment attribute is calculated by dividing the regression co-
efﬁcient of that attribute by the regression coefﬁcient of price
[10,13].
Results
Sample Characteristics
There were a total of 78 study participants (Table 1). Participants
presented with one of four health states: SDEP (n = 15), SDSP
(n = 24), MDEP (n = 3), and MDSP (n = 36). The average age
was approximately 48 years, with the majority being women,
married/common-law, and nonsmokers, had completed postsec-
ondary education, and had total annual household incomes
$60,000 or greater. More than 50% of participants were being
treated for back pain and migraine with 37% of participants
having depression. The average length of time with chronic pain
was 8 years, and participants had been attending the pain clinic
for an average of 28 months.
WTP
Table 2 shows the regression results from the base model. Note
that data for individuals presenting with MDEP were pooled
with individuals presenting with MDSP because there were only
three individuals who presented with MDEP. The positive co-
efﬁcient for improvements to pain-related disability and pain
intensity indicates that individuals preferred improvements to
their PRM. The negative coefﬁcient on price indicated that indi-
viduals preferred treatments that cost less. The magnitude of
the coefﬁcients indicates that individuals preferred greater
improvements in both pain-related disability and pain intensity.
Furthermore, the magnitude of the coefﬁcients for pain re-
duction were greater than those for disability improvement
indicating that respondents preferred pain reduction over
improvements in pain-related disability.
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Figure 3 shows the WTP results of the base model pooling
across all study participants. Conﬁdence intervals (CI) and sta-
tistical signiﬁcance were calculated from standard errors gener-
ated from 1000 bootstrap replications. Pooling across health
states indicate that overall, respondents were WTP $209 (95%
CI: $31–$388) P < 0.021 per month for a reduction to moderate
disability, $361 (95% CI: $200–$523) P < 0.001 per month for a
reduction to mild disability, $225 (95% CI: -$28–$477) P < 0.08
per month for a reduction to severe pain, $681 (95% CI $478–
$884) P < 0.001 per month for a reduction to moderate pain,
and $1067 (95% CI: $836–$1298) P < 0.001 per month for a
reduction to mild pain. The marginal WTP for a treatment that
reduced both disability and pain intensity to a mild severity was
$1428 per month ($361 + $1067).
Table 3 shows the results from the base + demographic model
for the pooled data (when pooling across all presenting PRHS).
Note that WTP is only calculated for statistically signiﬁcant
coefﬁcients. Older age was associated with lower WTP for a
reduction to mild pain. Compared to women, men were WTP
more for a reduction to mild pain but were WTP less for a
reduction to moderate pain. Compared to individuals who were
unmarried, married individuals were WTP more for a reduction
to mild disability. Compared to nonsmokers, smokers were WTP
more for a reduction to moderate disability and WTP less for a
reduction to severe pain. Compared to individuals with less than
$30,000 annual household income, individuals with $30,000 to
$59,999 annual household income were WTP more for a reduc-
tion to mild disability, and individuals with greater than $59,999
annual household income were WTP more for a reduction to
moderate pain and mild pain. Longer time as a patient was
associated with lower WTP for a reduction to moderate pain.
Compared to individuals without depression, individuals with
depression were WTP less for a reduction to mild disability and
mild pain.
Validity and Sensitivity Analysis
One hundred percent and 93.6% of participants passed the con-
sistency and transitivity checks, respectively. In the base models,
the pseudo R2 values ranged from 0.2 to 0.4. In the
base + exogenous models, the pseudo R2 values ranged from 0.4
to 0.9. Marginal effects in the base and base + exogenous models
were statistically signiﬁcant, and the pain and disability attributes
had the expected sign (+, -) andmagnitude. Incomewas positively
associated with higher WTP for improvements in both pain
intensity and pain-related disability. WTP was positively associ-
ated with both, reported preferences for treatment attributes and
treatments with greater improvements to pain intensity (in indi-
viduals presenting with greater pain intensity). In the pooled data,
there were statistically signiﬁcant differences in WTP between
respondents who indicated purchase uncertainty. Respondents
who indicated that they were certain of their choices had a lower
WTP for improvements in PRM. Compared to respondents who
were uncertain, the WTP for reducing pain intensity and pain-
related disability to a mild severity was, respectively, $269 and
$627 lower in respondents who were certain.
Table 1 Characteristics of study population (presented as %)
Variable SDEP SDSP MDEP MDSP All
Number of choice questions 25 18 16 11 —
Required sample size 15 21 24 35 95
Sample size 15 24 3 36 78
Demographics
Age (M SD) 48.6 14.8 46.7 11.9 47.6 21.3 47.6 18.9 47.5 16.0
Female sex 33.3 58.3 66.7 58.3 53.8
Married/common-law 46.7 66.7 66.7 61.1 60.3
Current smoker 46.7 45.8 0 38.9 41
Completed postsecondary education 60.0 50.0 66.7 50.0 52.6
Total annual household income
Less than $30,000 20.0 20.8 66.7 22.2 23.1
$30,000–$59,999 40.0 33.3 0 41.7 37.2
Greater than $59,999 40.0 45.8 33.3 36.1 39.7
Pain history
Number of years with pain (M SD) 7.7 4.5 7.1 5.8 23.7 37.5 7.5 6.4 7.9 8.9
Months as a patient (M SD) 34.5 21.8 30.1 44.2 17.4 22.8 23.4 18.5 27.4 29.4
Pain condition and depression
Abdominal 0 4.2 0 5.6 3.8
High back 6.7 12.5 0 0 5.1
Low back 53.3 25.0 33.3 36.1 35.9
Limb or joint 13.3 20.8 0 22.2 19.2
Chest 6.7 0 0 2.8 2.6
Headache or migraine 13.3 16.7 66.7 8.3 14.1
Neuropathic 0 0 0 5.6 2.6
Neuralgia 6.7 8.3 0 5.6 6.4
Other pain 0 12.5 0 13.9 10.3
Depression 66.7 33.3 33.3 41.7 37.2
WTP survey validity checks
Improvement unrealistic/unbelievable 8.3 0 0 10 3.6
Certain would buy treatments chosen 80.0 83.3 66.7 63.9 73.1
Survey was easy to understand 73.3 79.2 66.7 66.7 71.8
Trade-offs easy to make 46.7 66.7 66.7 55.6 57.7
Failed consistency check 0 0 0 0 0
Failed transitivity check 6.7 8.3 0 5.6 6.4
Indicated survey was consequential 80.0 83.3 66.7 72.2 76.9
Indicated protest bias 6.7 0 33.3 8.3 6.4
SDEP, severe disability and excruciating pain; SDSP, severe disability and severe pain; MDEP, moderate disability and excruciating pain; MDSP, moderate disability and severe pain; SD, standard
deviation,WTP, willingness to pay.
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Discussion
The societal impact of chronic pain is signiﬁcant and should be of
great concern to policymakers because of the rising prevalence
and escalating burden on already stretched health-care resources.
To provide insight, which may reinforce the need for more effec-
tive pain management strategies, and to quantify the economic
burden of the chronic pain health state, we measured the WTP
for reducing pain intensity and/or improving pain-related disabil-
ity for persons with chronic pain. Our results indicate that
persons with chronic pain are WTP signiﬁcant amounts to mini-
mize their PRM. Furthermore, WTP does vary by background
and clinical factors.
The base model showed that overall (i.e., pooled results),
persons with chronic pain are WTP $361 and $1067 per month to
improve pain-related disability and reduce pain intensity to a mild
severity, respectively. Nevertheless, WTP was lower in respon-
dents who indicated that they were certain of their treatment
choices. Thus, our sample population was WTP approximately
$17,000 per year to minimize PRM, as far as our hypothetical
choice model allowed. The average gross annual family income of
our sample (calculated by using the midpoint in income categories
as a point estimate) was $33,000, suggesting that our sample
population was willing to allocate 52% of their gross family
income to minimize their morbidity caused by chronic pain.
Policy Implications
In contrast with other approaches for valuing health (e.g.,
quality-adjusted life-years), monetizing health improvement
allows for direct monetary comparisons between the amount of
dollars invested in services that improve health and their asso-
ciated health improvement. To illustrate, we can estimate the
amount of health improvement, expressed in dollars that can be
generated from the resources invested to operate the Multidisci-
plinary Pain Centre. Consider the following: In 2007, the Mul-
tidisciplinary Pain Centre had 2234 patient visits. Assuming that
multidisciplinary treatment for chronic low back pain is 67%
effective at returning individuals to work in 6 months [21], which
is equivalent to an improvement to a moderate severity in PRM,
the amount of “health improvement” generated from these
patients was worth approximately $8 million per year
(1496 ¥ $890 ¥ 6). The average fee per physician visit is assumed
to be $177.56 per visit (fee code 03.08F) [22]. Therefore, the
total physician visit costs for the Multidisciplinary Pain Centre
was approximately $400,000 per year. Annual operating cost of
the Multidisciplinary Centre, including nursing, equipment, and
supplies, was approximately $180,000. Therefore, the return on
investment is approximately $7.4 million worth of health
improvement per year or $3318 per patient visit per year (Note:
this does inform whether resources could be applied more efﬁ-
ciently elsewhere).
Clinical Implications
From a clinical perspective, our results indicate that persons with
chronic pain strongly prefer pain reduction over disability
improvement (Fig. 3). Regardless of presenting severity in dis-
ability, for every dollar an individual was WTP to improve their
disability to the lowest severity (mild), he/she was WTP approxi-
mately $2 to reduce pain intensity to moderate and approxi-
mately $3 to reduce pain intensity to mild. This suggests that
treatment and management strategies that target pain intensity
over improvements in disability would have the greatest impact
on improving health-related quality of life for persons with
chronic pain.Ta
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Our results, therefore, support a refocusing of clinicians
efforts toward reducing pain intensity instead of focusing on the
acceptance of pain and the pursuit of normal life activities [23].
This is a difﬁcult notion for many clinicians who are faced with
the challenge of trading the risks of what chronic patients prefer,
which we found above all else is a reduction in pain intensity,
with the real concerns about the risk, safety, and uncertainty of
treatments currently available. Further research should elucidate
the trade-off between risks and beneﬁts from a patient perspec-
tive and hence provide insight for developing clinical guidelines
around the use of effective, yet potentially harmful treatments.
Strengths and Limitations
There are several strengths to our analysis, which increase the
validity of our ﬁndings. First, tests for consistency and transitiv-
ity conﬁrm that the large majority of respondents were not using
heuristics. Second, WTP was positively associated with higher
income and with self-reported preferences for attributes of pain
reduction, indicating that our results are consistent with under-
lying theory. Construct validity was further evidenced by the fact
that model coefﬁcients were statistically signiﬁcant, had the
expected sign (+, -), that WTP increased with greater improve-
ment in pain intensity in individuals presenting with greater
pain severity, and that the association between WTP and
demographic/clinical variables were consistent with our a priori
hypotheses and existing published research.
Our results, however, should also be evaluated in light of
study limitations. First, WTP for improvements in PRM is inﬂu-
enced by factors such as efﬁcacy, safety, time to relief, side effects,
and duration of effect [24,25]. It is important to reiterate that our
objective was to provide a measure that represented the burden
of the chronic pain health state itself and not to valuate any
speciﬁc type of treatment characteristics or modes of administra-
tion. Nevertheless, we acknowledge that WTP is inﬂuenced by
other factors that, when taken into account, would likely reduce
our WTP estimates. For instance, in a study of pharmaceutical
treatment for chronic migraineurs, Lenert [25] found that com-
pared to an ideal treatment (e.g., immediate relief and no side
effects), WTP was reduced by 43% for treatments, with a chance
of rebound headache, being unable to go to work, delay in relief,
and shorter duration of relief. Thus, our results reﬂect the valu-
ation of the chronic pain health state, which can be considered an
upper bound estimate of chronic pain patients’ WTP for
improvements in PRM.
Second, our results are limited in the applicability for inform-
ing societal prioritizations for two primary reasons. The WTP
valuations are based on patient preferences for improvements in
PRM and do not reﬂect societal preferences. Additionally, WTP
is affected by ability to pay (i.e., income), and only 40% of our
study population had family incomes greater than $50,000 per
year that is likely not representative of the family income of
the average taxpayer in Alberta, which was $78,400 in 2006
(Statistics Canada: http://www40.statcan.ca/l01/cst01/famil108
a.htm?sdi=family%20income). Although valuing the chronic pain
health state requires valuations from individuals who have expe-
rienced chronic pain opposed to the general population, the WTP
results do not inform the value that society in general places on
improving PRM.
Third, the severity of chronic pain in our study population was
not representative of the severity of chronic pain sufferers who can
be satisfactorily managed by their primary care physician. There-
fore, our results can only be generalized to persons with chronic
pain whose severity necessitates care beyond those offered by
primary care. Nevertheless, given the extant research and our
interactions with other tertiary care multidisciplinary pain centers
across the world, it is our impression that the population sampled
in this study would be similar to that of other tertiary care
multidisciplinary pain centers in most developed countries. This,
however, remains to be resolved by future WTP research con-
ducted in other chronic pain settings, including tertiary care and
primary care populations.
Fourth, to minimize bias resulting from strategic behavior, we
excluded individuals who were involved in litigation or an insur-
ance claim. We also only included individuals who were 20 years
or older who were not newly referred patients. Consequently, the
study inclusion and exclusion criteria introduce the possibility
for selection bias. Therefore, it must be emphasized that our
results reﬂect the WTP of individuals who were 20 years and
older, not newly admitted patients, and who were not involved in
litigation or an insurance claim. Approximately 5% of the ran-
domly selected participants were involved in litigation or an
insurance claim and were excluded from the study population.
Compensation for injury is an important issue and valuing the
WTP for pain relief in individuals involved in litigation or insur-
ance would provide insight into issues around compensation for
pain and suffering.
Fifth, although various methods (e.g., in-person administra-
tion and cheap talk script) were employed to increase the validity
of the choice responses (discussed in methods section), it is not
certain whether the WTP estimates reﬂect what would have been
observed in a real market. It is important to point out that real
markets for treatments available for the level of severity in this
patient population do not exist in a publicly funded health-care
Figure 3 Willingness to pay for improvements to
pain intensity and/or pain-related disability using
pooled data. Note: WTP is calculated for coefﬁ-
cients that were statistically signiﬁcant shown in
Table 2. Conﬁdence intervals and P-values were
calculated from standard errors generate from
1000 bootstrap replications.
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system. The WTP for reducing pain intensity and pain-related
disability to a mild severity was, respectively, $269 and $627
lower in respondents who were certain than in respondents who
were uncertain of their choice responses.
Conclusion
In conclusion, four main points emerge from the study. First, the
morbidity associated with severe chronic pain is worth approxi-
Table 3 Nested logistic regression coefﬁcients for base + exogenous model pooled data
Attributes b 95% CI P-value
Constants
Constant treatment A 0.03 -0.50–0.56 0.886
Constant treatment B 0.02 -0.32–0.35 0.92
Disability improvement
Reduced to mild 1.08 0.45–1.71 <0.001
Reduced to moderate 1.59 0.37–2.80 0.01
Pain improvement
Reduced to mild 3.66 2.86–4.47 <0.001
Reduced to moderate 2.39 1.66–3.12 <0.001
Reduced to severe 1.35 -1.04–3.74 0.27
Price -0.0029 -0.0032–-0.0026 <0.001
Demographic
Reduced to mild disability ¥ age -0.01 -0.02–0.00 0.21
Reduced to moderate disability ¥ age -0.01 -0.03–0.02 0.61
Reduced to mild pain ¥ age -0.03 -0.04–-0.01 <0.001
Reduced to moderate pain ¥ age -0.01 -0.02–0.01 0.25
Reduced to severe pain ¥ age -0.01 -0.08–0.05 0.70
Reduced to mild disability ¥ sex 0.05 -0.13–0.23 0.59
Reduced to moderate disability ¥ sex -0.06 -0.32–0.21 0.68
Reduced to mild pain ¥ sex 0.28 0.07–0.49 0.01
Reduced to moderate pain ¥ sex 0.15 -0.05–0.35 0.13
Reduced to severe pain ¥ sex -0.54 -1.06–-0.02 0.04
Reduced to mild disability ¥married 0.40 0.20–0.60 <0.001
Reduced to moderate disability ¥married -0.03 -0.33–0.27 0.86
Reduced to mild pain ¥married 0.18 -0.05–0.42 0.13
Reduced to moderate pain ¥married 0.05 -0.17–0.27 0.66
Reduced to severe pain ¥married -0.06 -0.62–0.50 0.83
Reduced to mild disability ¥ smoker 0.07 -0.12–0.27 0.46
Reduced to moderate disability ¥ smoker 0.36 0.05–0.67 0.02
Reduced to mild pain ¥ smoker 0.21 -0.02–0.45 0.08
Reduced to moderate pain ¥ smoker 0.08 -0.14–0.30 0.48
Reduced to severe pain ¥ smoker -0.69 -1.27–-0.12 0.02
Reduced to mild disability ¥ education 0.15 -0.05–0.34 0.14
Reduced to moderate disability ¥ education -0.01 -0.29–0.28 0.97
Reduced to mild pain ¥ education 0.03 -0.20–0.27 0.78
Reduced to moderate pain ¥ education -0.01 -0.23–0.21 0.93
Reduced to severe pain ¥ education 0.01 -0.59–0.61 0.98
Reduced to mild disability ¥ income 30 k–59 k 0.45 0.20–0.71 <0.001
Reduced to moderate disability ¥ income 30 k–59 k 0.11 -0.24–0.47 0.54
Reduced to mild pain ¥ income 30 k–59 k 0.16 -0.13–0.46 0.28
Reduced to moderate pain ¥ income 30 k–59 k 0.03 -0.25–0.31 0.84
Reduced to severe pain ¥ income 30 k–59 k -0.03 -0.68–0.61 0.92
Reduced to mild disability ¥ income >59 k -0.13 -0.43–0.16 0.38
Reduced to moderate disability ¥ income >59 k 0.20 -0.22–0.61 0.35
Reduced to mild pain ¥ income >59 k 1.03 0.66–1.39 <0.001
Reduced to moderate pain ¥ income >59 k 0.69 0.36–1.03 <0.001
Reduced to severe pain ¥ income >59 k 0.66 -0.28–1.60 0.17
Clinical
Reduced to mild disability ¥months as a patient 0.01 0.00–0.01 0.22
Reduced to moderate disability ¥months as a patient 0.01 -0.01–0.01 0.77
Reduced to mild pain ¥months as a patient 0.01 0.00–0.01 0.19
Reduced to moderate pain ¥months as a patient -0.01 -0.02–0.00 0.02
Reduced to severe pain ¥months as a patient -0.02 -0.04–0.00 0.13
Reduced to mild disability ¥ years with pain 0.00 -0.02–0.02 0.73
Reduced to moderate disability ¥ years with pain -0.04 -0.10–0.02 0.17
Reduced to mild pain ¥ years with pain 0.00 -0.03–0.02 0.71
Reduced to moderate pain ¥ years with pain 0.00 -0.02–0.03 0.79
Reduced to severe pain ¥ years with pain 0.02 -0.02–0.06 0.35
Reduced to mild disability ¥ number of comorbidities 0.00 -0.14–0.14 0.99
Reduced to moderate disability ¥ number of comorbidities -0.13 -0.34–0.08 0.23
Reduced to mild pain ¥ number of comorbidities 0.07 -0.09–0.23 0.41
Reduced to moderate pain ¥ number of comorbidities 0.00 -0.15–0.15 1.00
Reduced to severe pain ¥ number of comorbidities 0.16 -0.42–0.75 0.58
Reduced to mild disability ¥ depressed -0.25 -0.47–-0.04 0.02
Reduced to moderate disability ¥ depressed 0.13 -0.25–0.52 0.50
Reduced to mild pain ¥ depressed -0.29 -0.54–-0.04 0.03
Reduced to moderate pain ¥ depressed -0.07 -0.31–0.16 0.54
Reduced to severe pain ¥ depressed 0.54 -0.29–1.36 0.20
Note that only statistically signiﬁcant coefﬁcients are included in the calculation of WTP.
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mately $1428 for every month in the chronic pain health state.
Second, treatment and management strategies that focus on
reducing pain intensity would have the greatest impact on
improving health-related quality of life. Third, valuing health
improvement in monetary terms provide an opportunity for
making direct monetary comparisons between the resource
investment in interventions targeting chronic pain and the health
return on that investment. Finally, future research in pain valu-
ation should focus on the trade-off between treatment risk
and beneﬁts from a patient perspective to provide guidance
around the use of potentially harmful treatments with known
effectiveness.
Source of ﬁnancial support: The authors declare no ﬁnancial or other
relationship that might lead to a conﬂict of interest. This research was not
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